{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:40:47Z","timestamp":1792294847620,"version":"4.4.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.urolonc.2026.09.003","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:18:36Z","timestamp":1791026316000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5570-8792","authenticated-orcid":false,"given":"David-Dan","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Satkunasivam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jethro C.C.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobby","family":"Shayegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aly-Khan","family":"Lalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey T.","family":"Gotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda E.","family":"Hird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kokorovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Rendon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney H.","family":"Breau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Finelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish S.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre R.","family":"Zlotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.D.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2026.09.003_bib0001","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.eururo.2018.07.027","article-title":"Systematic review of systemic therapies and therapeutic combinations with local treatments for high-risk localized prostate cancer","volume":"75","author":"Tosco","year":"2019","journal-title":"Eur Urol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2026.09.003_bib0002","doi-asserted-by":"crossref","first-page":"TPS285","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS285","volume":"40","author":"Kibel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.09.003_bib0003","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2603878","article-title":"Perioperative apalutamide in high-risk localized prostate cancer","author":"Taplin","year":"2026","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2026.09.003_bib0004","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.urolonc.2019.12.014","article-title":"Definition of high-risk prostate cancer impacts oncological outcomes after radical prostatectomy","volume":"38","author":"Knipper","year":"2020","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.09.003_bib0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.euo.2018.02.004","article-title":"Heterogeneity in definitions of high-risk prostate cancer and varying impact on mortality rates after radical prostatectomy","volume":"1","author":"Mossanen","year":"2018","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.09.003_bib0006","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN Guidelines\u00ae insights: prostate Cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.urolonc.2026.09.003_bib0007","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/cncr.10657","article-title":"Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era","volume":"95","author":"D\u2019Amico","year":"2002","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.urolonc.2026.09.003_bib0008","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"J Am Med Assoc"},{"issue":"6","key":"10.1016\/j.urolonc.2026.09.003_bib0009","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/jamasurg.2021.0528","article-title":"STROBE reporting guidelines for observational studies","volume":"156","author":"Ghaferi","year":"2021","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.urolonc.2026.09.003_bib0010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.juro.2008.09.027","article-title":"The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival","volume":"181","author":"Nguyen","year":"2009","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.09.003_bib0011","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.juro.2007.03.105","article-title":"Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods","volume":"178","author":"Yossepowitch","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.09.003_bib0012","doi-asserted-by":"crossref","first-page":"S1743","DOI":"10.1016\/j.annonc.2025.09.102","article-title":"LBA86 Randomised phase III trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)","volume":"36","author":"Nguyen","year":"2025","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2026.09.003_bib0013","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300023","article-title":"Artificial intelligence predictive model for hormone therapy use in prostate cancer","volume":"2","author":"Spratt","year":"2023","journal-title":"NEJM Evid"},{"issue":"12","key":"10.1016\/j.urolonc.2026.09.003_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.38550","article-title":"Performance of a prostate-specific membrane antigen positron emission tomography\/computed tomography\u2013derived risk-stratification tool for high-risk and very high-risk prostate cancer","volume":"4","author":"Xiang","year":"2021","journal-title":"JAMA Netw Open"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926007313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926007313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:10:36Z","timestamp":1792293036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926007313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":14,"alternative-id":["S1078143926007313"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.09.003","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}